Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

rho Is Not Essential for Viability or Virulence inStaphylococcus aureus

Robert S. Washburn, Andrea Marra, Alexander P. Bryant, Martin Rosenberg, Daniel R. Gentry
Robert S. Washburn
GlaxoSmithKline, Collegeville, Pennsylvania 19426
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Marra
GlaxoSmithKline, Collegeville, Pennsylvania 19426
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander P. Bryant
GlaxoSmithKline, Collegeville, Pennsylvania 19426
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Rosenberg
GlaxoSmithKline, Collegeville, Pennsylvania 19426
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel R. Gentry
GlaxoSmithKline, Collegeville, Pennsylvania 19426
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.45.4.1099-1103.2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

We have identified the gene for transcription termination factor Rho in Staphylococcus aureus. Deletion ofrho in S. aureus reveals that it is not essential for viability or virulence. We also searched the available bacterial genomic sequences for homologs of Rho and found that it is broadly distributed and highly conserved. Exceptions includeStreptococcus pneumoniae, Streptococcus pyogenes, Mycoplasma genitalium, Mycoplasma pneumoniae, Ureaplasma urealyticum, and Synechocystis sp. strain PCC6803, all of which appear not to possess a Rho homolog. Complementation studies indicate that S. aureus Rho possesses the same activity as Escherichia coli Rho and that the Rho inhibitor bicyclomycin is active against S. aureus Rho. Our results explain the lack of activity of bicyclomycin against many gram-positive bacteria and raise the possibility that the essentiality of rho may be the exception rather than the rule.

The rho gene codes for transcription termination factor Rho (19) and is essential for the viability of Escherichia coli (5). The function of Rho is to catalyze the release of RNA from a transcription complex after a Rho-dependent terminator sequence has been transcribed. Rho has an RNA-dependent NTPase activity, which is required for transcript release (10, 12), and an RNA-DNA helicase activity (1). Several Rho-dependent transcription terminators in Escherichia coli and coliphage λ are known (4, 20).

Rho is a hexamer of identical 47-kDa monomers (2, 9, 11, 17). Its ability to bind RNA is thought to be conferred by residues 22 to 116 of the 419-amino-acid protein (14). The ATP binding domain is located between residues 167 and 319 (7). No activity has been assigned to the essential C terminus of Rho, although it has been speculated as being involved in subunit interactions (1, 6, 8).

The antibiotic bicyclomycin inhibits Rho (23). With the exception of Micrococcus luteus (15, 16), gram-positive bacteria are resistant to bicyclomycin, andrho is not essential in the gram-positive bacteriumBacillus subtilis (13, 21). This study reports the sequence and characterization of the rho gene in the clinically important gram-positive pathogen Staphylococcus aureus.

MATERIALS AND METHODS

Bacteria and growth conditions. Staphylococcus aureus was propagated in either tryptic soy broth (DIFCO) or Luria broth (LB). E. coli was grown in LB. For auxotrophy measurements with S. aureus, M9 minimal medium was supplemented with arginine, cysteine, glutamate, glycine, isoleucine, leucine, methionine, proline, and valine, all at 20 μg/ml. Nicotinate and thiamine were added at 0.2 μg/ml. All cultures were routinely incubated at 37°C. All strains used in this study are described in Table 1.

View this table:
  • View inline
  • View popup
Table 1.

Strains and plasmids used in this study

Identification of the S. aureus rho gene.Therho gene from Staphylococcus aureus was identified from an S. aureus genomic sequence database by homology with E. coli rho. The plasmid pAU2442 used in this study is from a genomic library used in the sequencing project.

Deletion mutagenesis.A rho deletion was introduced into S. aureus RN4220. This was achieved by electroporating S. aureus RN4220 to tetracycline resistance (Tcr) with pRW101, which has the rhogene with 500 bp of flanking sequence interrupted by a tetracyline resistance marker that replaces the rho gene from codon 1 to codon 313 (Fig. 1). The resulting Tcr colonies were then screened for erythromycin resistance (Emr), which is carried elsewhere on pRW101. Tcr Ems colonies indicated a double-crossover event occurred. The deletion ofrho was confirmed by PCR analysis with primers flanking the Tcr marker. To construct a Δrhostrain in a pathogenic background, the Δrho::tet mutation was moved into theS. aureus clinical isolate WCUH29 by bacteriophage Φ11 transduction. The resulting strain, RSW101, was used in virulence testing as described below.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Sequence of S. aureus rho and flanking sequences used in this report. Shown is the DNA sequence of the region of the S. aureus chromosome that containsrho. The rho gene product is shown below its coding sequence. DNA sequence with a strikethrough line depicts the sequence deleted in the rho deletion-insertion strain described in this paper.

Complemention of E. coli rho. E. coli rho was replaced with S. aureus rho by introducing theS. aureus rho-containing plasmid pAU2442 into the E. coli rho deletion strain BLS107(pPMrho). This strain has a deletion-insertion (rho::kan) mutation in the chromosomal copy of rho. A wild-type copy ofrho is carried on the plasmid pPMrho, which has a temperature-sensitive replicon. This strain fails to grow at 42°C due to the loss of rho at this temperature (22). pAU2442 was introduced into BLS107(pPMrho) by electroporation and was plated at 30, 37, and 42°C. As a control, the parent strain was also plated at the different temperatures. While the parent strain failed to form isolated colonies at 37 and 42°C, the strain containing pAU2442 grew well and formed isolated colonies at all temperatures. The loss of pPMrho was confirmed by scoring for loss of chloramphenicol resistance, which is encoded by this plasmid. To determine if the S. aureus Rho protein is sensitive to bicyclomycin, strain BLS107(pAU2442) was tested for sensitivity by MIC determination. Liquid MICs were determined by a serial dilution method. Strain BLS107 was found to have an MIC of bicyclomycin of 125 μg/ml. This is twofold lower than that of the wild-type E. coli strain MG1655 (250 μg/ml). The MIC for the S. aureus strain RN4220 was found to be >2.5 mg/ml.

Virulence testing.The rho deletion strain RSW101 and its wild-type parent, WCUH29, were tested for virulence with two mouse S. aureus infection models. The surgical wound model measures the ability to grow on sutures sewn in the skin of healthy mice, while the hematogenous pyelonephritis model measures the ability of the strains to cause kidney infections following parenteral infection with the bacteria.

Surgical wound infections.The mice used for these infections were 4- to 6-week-old male CD-1 mice. Approximately 15-cm sutures were soaked in overnight cultures of WCUH29 and RSW101 for 30 min at room temperature. The backs of the mice were shaved, the animals were anesthetized with isoflurane, and an ∼2-cm-long incision was made along the animals' backs. The infected sutures were secured at one end of the wound and tacked once midway along the wound on the underside of the skin. The suture was then secured at the other end of the wound, and the wound was closed with a single staple. After 5 days, the mice were sacrificed by CO2 overdose. The skin surrounding the wound was excised and then homogenized in 1 ml of phosphate-buffered saline (PBS) in a stomacher, and bacterial viable counts were enumerated. Both infections yielded over 106 bacteria after 5 days, with no significant difference observed between the strains. For the hematogenous pyelonephritis model, bacterial recovery rates (mean ± standard deviation; n = 5) were 5.35 ± 0.41 log10 CFU/ml for strain WCUH29 and 6.44 ± 0.81 log10 CFU/ml for strain WCUH29 Δrho. For the surgical wound model, the recovery rates were 6.58 ± 0.78 log10 CFU/ml for strain WCUH29 and 7.41 ± 0.57 log10 CFU/ml for strain WCUH29 Δrho. One hundred colonies isolated from the rho mutant infection were checked for tetracycline resistance, indicative of the presence of the mutation, and all were found to be tetracycline resistant.

Hematogenous pyelonephritis infections.Six- to eight-week-old male CD-1 mice were used for hematogenous pyelonephritis infections. Cultures of WCUH29 and RSW101 cells were adjusted to an A600 of 0.6 or 0.3 per ml, and 200 μl was injected into each mouse via a tail vein. Mice were sacrificed on day 5 postinfection by CO2overdose, and their kidneys were aseptically removed and then homogenized in 1 ml of PBS in a stomacher, and viable counts were enumerated (described above). The inoculum for both strains was 107 cells. The number of bacteria recovered from the kidneys infected with RSW101 after 5 days was not decreased. One hundred colonies from the RSW101 infection were checked for the tetracycline resistance marker, and 98% were found to be tetracycline resistant.

Nucleotide sequence accession number.The nucleotide sequence of the S. aureus rho gene has been deposited in GenBank under accession no. AF333962.

RESULTS

The S. aureus Rho protein.S. aureusRho is predicted to code for a 443-amino-acid protein with a predicted molecular mass of 50 kDa. S. aureus Rho is 53% identical and 67% similar to E. coli Rho and 66% identical and 75% similar to B. subtilis Rho (Fig.2). The predicted ATPase domain (residues 167 to 342 of E. coli Rho) is highly conserved among different bacterial species (18). The predicted ATPase domain of S. aureus Rho (residues 180 to 356) is 80% similar and 70% identical to E. coli Rho and 86% similar and 81% identical to B. subtilis Rho. Finally, the predicted RNA binding domain of S. aureus Rho (residues 40 to 132) has 63% similarity and 41% identity to E. coli Rho and 77% similarity and 60% identity to B. subtilis Rho.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Alignment of S. aureus Rho withB. subtilis and E. coli Rho. Sequences were aligned by using the MegAlign program of the DNAstar DNA analysis package. Identical residues are shaded.

Complementation.The S. aureus rho gene can complement the lack of growth of an E. coli strain withrho deleted.. This was determined by curing arho-deleted strain of a plasmid that carries E. coli rho in the presence of S. aureus rho carried on another plasmid. The sole Rho activity in the resulting strain, BLS107(pAU2442), is from S. aureus Rho. Strain BLS107(pAU2442) is sensitive to bicyclomycin, as indicated by the bicyclomycin MIC of 125 μg/ml, indicating thatS. aureus Rho is inhibited by bicyclomycin. As further evidence of this, bicyclomycin was found to inhibit the ATPase activity of partially purified S. aureus Rho (data not shown).

The S. aureus rho gene is not essential for in vitro growth.A Δrho strain, RSW100, was constructed by replacing nearly all of the rho gene with a tetracycline resistance cassette (Fig. 1). The resulting strain is viable and grows normally at 30, 37, 42, and 46°C. RSW100 also grows normally on rich medium (LB or tryptic soy broth) or minimal medium (supplemented M9 medium) and under anaerobic conditions (data not shown).

rho is not required for S. aureusvirulence.The rho deletion was transduced into the pathogenic clinical isolate WCUH29, yielding strain RSW101. Cultures of WCUH29 and RSW101 were used in the two in vivo models described in Materials and Methods. S. aureus strains mutated in a variety of different genes affecting cell metabolism or virulence have been examined in our laboratories. These strains have displayed reductions of up to 3 logs in the pyelonephritis model and 1 log in the surgical wound infection. In the experiments described here, the in vivo growth of RSW101 was not impaired compared to that of wild-type WCUH29 in either of the model systems. From these data, we conclude that, as with in vitro growth, rho is not essential for the virulence of the strain tested.

Review of Rho homologs present in public sequence database.By using the S. aureus Rho sequence as a query, we searched the public databases and some proprietary sequence databases for homologs. Rho was found to be highly conserved; BLAST scores were 5 × 10−38 or lower for all full-length Rho sequences annotated as such. As indicated previously by Opperman and Richardson (18), Rho is broadly distributed among all the major phyla of the eubacteria (Table 2). A major exception to the universal presence of Rho among the eubacteria are the members of the low-GC, gram-positive bacteria Streptococus pyogenes, Streptococcus pneumoniae, Mycoplasma genitalium, M. pneumoniae, and Ureaplasma urealyticum, all of which do not possess a significant homolog. In the case of S. pneumoniae, we searched several proprietary databases in addition to publicly available databases and failed to identify a homolog. In addition to the mentioned bacteria,Synechocystis sp. strain PCC6803, a cyanobacterium, also apparently lacks a Rho homolog. As indicated previously (18), the ATP binding motif of Rho shares homology with the α and β subunits of F1 ATPases. This homology is conserved among the bacteria as well.

View this table:
  • View inline
  • View popup
Table 2.

Bacterial phyla with members that possess a Rho homologa

DISCUSSION

In this report, we show that the S. aureus rho gene can complement an E. coli rho deletion strain. The ability ofS. aureus rho to replace the essential E. coli rho gene raises the possibility that it performs the same functions in S. aureus and E. coli. rho is not essential in the low-GC, gram-positive bacteriumBacillus subtilis (13, 21), and several gram-positive species, including Staphylococcus aureus, are resistant to the Rho inhibitor bicyclomycin (15). Here we show that rho is not required for viability or virulence inS. aureus. The E. coli strain constructed here, which has had its own rho gene replaced with S. aureus rho, remains sensitive to bicyclomycin. This suggests that the resistance of gram-positive bacteria to bicyclomycin is a result of the nonessentiality of Rho. Supporting this conclusion and extending the lack of essentiality of rho to other genera, we found that the completed genomes of several members of the low-GC, gram-positive bacteria lack a Rho homolog. The cyanobacteriumSynechocystis sp. strain PCC6803 was also found to lack a Rho homolog.

An open question is why rho should be essential in E. coli and other gram-negative bacteria, but not be essential in some gram-positive bacteria. It could be that Rho activity is redundant in the bacteria where it is not essential. This possibility cannot be readily discounted, but it is clear that the enzyme responsible for this redundant activity would have to have no sequence homology with Rho for this to be the case. A second possibility, that Rho is essential for organisms with a higher GC content, seems unlikely, given that Synechocystis sp. strain PCC6803 also lacks Rho, and yet its genome is 47% GC, close to that of E. coli. The lack of rho among several members of the low-GC, gram-positive bacteria and a member of the very distantly related cyanobacteria could indicate a trend that the essentiality ofrho may be more the exception than the rule. Because of this, a more informative approach to the question is to ask whyrho is essential in E. coli and other gram-negative bacteria. There are only a few Rho-dependent terminators in E. coli; the vast majority of E. coli operons contain factor-independent terminators. Furthermore, it is not obvious why inhibition of termination at Rho-dependent terminators would lead to a lethal event. It might be that there is some other function of Rho that better explains its essential nature in some bacteria.

FOOTNOTES

    • Received 15 November 2000.
    • Returned for modification 29 December 2000.
    • Accepted 11 January 2001.
  • Copyright © 2001 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Bear D. G.,
    2. Andrews C. L.,
    3. Singer J. D.,
    4. Morgan W. D.,
    5. Grant R. A.,
    6. von Hippel P. H.,
    7. Platt T.
    Escherichia coli transcription termination factor Rho has a two-domain structure in its activated form. Proc. Natl. Acad. Sci. USA 82 1985 1911 1915
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Bear D. G.,
    2. Hicks P. S.,
    3. Escudero K. W.,
    4. Andrews C. L.,
    5. McSwiggen J. A.,
    6. von Hippel P. H.
    Interactions of Escherichia coli transcription termination factor Rho with RNA. J. Mol. Biol. 199 1988 623 635
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.
    1. Brennan C. A.,
    2. Dombroski A. J.,
    3. Platt T.
    Transcription termination factor Rho is an RNA-DNA helicase. Cell 48 1987 945 952
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Das A.
    Control of transcription termination by RNA binding proteins. Annu. Rev. Biochem. 62 1993 893 930
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Das A.,
    2. Court D.,
    3. Adhya S.
    Isolation and characterization of conditional lethal mutants of Escherichia coli defective in transcription termination factor rho. Proc. Natl. Acad. Sci. USA 73 1976 1959 1963
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Dolan J. W.,
    2. Marshall N. F.,
    3. Richardson J. P.
    Transcription termination factor Rho has three distinct structural domains. J. Biol. Chem. 265 1990 5747 5754
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Dombroski A. J.,
    2. LaDine J. R.,
    3. Cross R. L.,
    4. Platt T.
    The ATP binding site on rho protein. Affinity labelling of Lys181 by pyridoxal 5′-diphospho-5′-adenosine. J. Biol. Chem. 263 1988 18810 18815
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Dombroski A. J.,
    2. Platt T.
    Structure of ρ factor: an RNA-binding domain and a separate region with strong similarity to ATP-binding domains. Proc. Natl. Acad. Sci. USA 85 1988 2538 2542
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Finger L. R.,
    2. Richardson J. P.
    Stabilization of the hexameric form of Escherichia coli protein rho under ATP hydrolysis conditions. J. Mol. Biol. 156 1982 203 219
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Galluppi G. R.,
    2. Lowery C.,
    3. Richardson J. P.
    Nucleoside triphosphate requirement for termination of RNA synthesis by rho factor RNA polymerase. Losick R., Chamberlin M. 1976 657 665 Cold Spring Harbor Laboratory Press Cold Spring Harbor, N.Y
  11. 11.↵
    1. Gogol E. P.,
    2. Seifred S. E.,
    3. von Hippel P. H.
    Structure and assembly of the Escherichia coli transcription termination factor Rho and its interactions with RNA. I. Cryoelectron microscopic studies. J. Mol. Biol. 221 1991 1127 1138
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Howard B. H.,
    2. de Crombrugghe B.
    ATPase activity required for termination of transcription by the Escherichia coli protein factor ρ. J. Biol. Chem. 251 1976 2520 2524
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Ingham C. J.,
    2. Dennis J.,
    3. Furneaux P. A.
    Autogenous regulation of transcription termination factor Rho and the requirement for Nus factors in Bacillus subtilis. Mol. Microbiol. 31 1999 651 653
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Modrak D.,
    2. Richardson J. P.
    The RNA-binding domain of transcription termination factor Rho: isolation, characterization and determination of sequence limits. Biochemistry 33 1994 8292 8299
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Nishida M.,
    2. Mine Y.,
    3. Matsubara T.
    Bicyclomycin, a new antibiotic. III. In vitro and in vivo antimicrobial activity. J. Antibiot. 25 1972 582 593
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Nowatzke W. L.,
    2. Keller E.,
    3. Koch G.,
    4. Richardson J. P.
    Transcription termination factor Rho is essential for Micrococcus luteus. J. Bacteriol. 179 1997 5238 5240
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Oda T.,
    2. Takanami M.
    Observations on the structure of the termination factor Rho and its attachment to DNA. J. Mol. Biol. 71 1972 799 802
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Opperman T.,
    2. Richardson J. P.
    Phylogenetic analysis of sequences from diverse bacteria with homology to the Escherichia coli rho gene. J. Bacteriol. 176 1994 5033 5043
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Pinkham J. L.,
    2. Platt T.
    The nucleotide sequence of the rho gene of E. coli K-12. Nucleic Acids Res. 11 1983 3531 3545
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Platt T.,
    2. Richardson J. P.
    Escherichia coli Rho factor: protein and enzyme of transcription termination Transcriptional regulation. McKnight S. L., Yamamoto K. R. 1992 365 388 Cold Spring Harbor Laboratory Press Cold Spring Harbor, N.Y
  21. 21.↵
    1. Quirk P. G.,
    2. Dunkley E. A. Jr.,
    3. Lee P.,
    4. Krulwich T. A.
    Identification of a putative Bacillus subtilis rho gene. J. Bacteriol. 175 1993 647 654
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Washburn R. S.,
    2. Stitt B. L.
    In vitro characterization of transcription termination factor Rho from Escherichia coli rho(nusD) mutants. J. Mol. Biol. 260 1996 332 346
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Zwiefka A.,
    2. Kohn H.,
    3. Widger W. R.
    Transcription termination factor rho: The site of bicyclomycin inhibition in Escherichia coli. Biochemistry 32 1993 3564 3570
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
rho Is Not Essential for Viability or Virulence inStaphylococcus aureus
Robert S. Washburn, Andrea Marra, Alexander P. Bryant, Martin Rosenberg, Daniel R. Gentry
Antimicrobial Agents and Chemotherapy Apr 2001, 45 (4) 1099-1103; DOI: 10.1128/AAC.45.4.1099-1103.2001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
rho Is Not Essential for Viability or Virulence inStaphylococcus aureus
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
rho Is Not Essential for Viability or Virulence inStaphylococcus aureus
Robert S. Washburn, Andrea Marra, Alexander P. Bryant, Martin Rosenberg, Daniel R. Gentry
Antimicrobial Agents and Chemotherapy Apr 2001, 45 (4) 1099-1103; DOI: 10.1128/AAC.45.4.1099-1103.2001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Rho Factor
Staphylococcus aureus
rho GTP-Binding Proteins

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596